Von Hippel–Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein

Von Hippel–Lindau (VHL) disease is characterized by frequent mutation of VHL protein, a tumor suppressor that functions as the substrate recognition subunit of a Cullin2 RING E3 ligase complex (CRL2(VHL)). CRL2(VHL) plays important roles in oxygen sensing by targeting hypoxia-inducible factor-alpha...

Descripción completa

Detalles Bibliográficos
Autores principales: Frost, Julianty, Rocha, Sonia, Ciulli, Alessio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313594/
https://www.ncbi.nlm.nih.gov/pubmed/34174286
http://dx.doi.org/10.1016/j.jbc.2021.100910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313594/
https://www.ncbi.nlm.nih.gov/pubmed/34174286
http://dx.doi.org/10.1016/j.jbc.2021.100910

Ejemplares similares